A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications

Despite considerable treatment progress, cancer remains among the leading causes of death worldwide. Antibody-drug conjugates (ADCs), a rapidly growing class of systemic therapy, show promise by combining the properties of conventional chemotherapy and targeted therapy. Antibody-drug conjugates have...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical medicine 2024, Vol.38 (1), p.39-54
Main Authors: Kesireddy, Meghana, Kothapalli, Srikanth Reddy, Gundepalli, Sai Giridhar, Asif, Samia
Format: Article
Language:English
Subjects:
Antigens
Biomedical and Life Sciences
Biomedicine
Cancer therapies
Cell cycle
Cell death
Chemotherapy
Clinical trials
Cytotoxicity
FDA approval
Lymphoma
Monoclonal antibodies
Neutropenia
Pharmaceutical Sciences/Technology
Pharmacology/Toxicology
Pharmacotherapy
Review Article
RNA polymerase
Stem cell transplantation
Thrombocytopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite considerable treatment progress, cancer remains among the leading causes of death worldwide. Antibody-drug conjugates (ADCs), a rapidly growing class of systemic therapy, show promise by combining the properties of conventional chemotherapy and targeted therapy. Antibody-drug conjugates have been shown to be more efficacious than traditional chemotherapy. To date, there are 13 ADCs approved by the United States Food and Drug Administration (FDA) for treating various hematological and solid organ cancers. There are several new promising ADCs that are being developed and are in clinical trials. This review provides an overview of the current FDA-approved ADCs, the landmark clinical trials that led to their approval, the common toxicities seen in the landmark trials, the challenges associated with ADCs, and the potential future directions.
ISSN:1178-2595
1179-1993
DOI:10.1007/s40290-023-00505-8